Quadrant Capital Group LLC decreased its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN – Free Report) by 67.3% during the third quarter, HoldingsChannel.com reports. The fund owned 13,457 shares of the medical equipment provider’s stock after selling 27,717 shares during the period. Quadrant Capital Group LLC’s holdings in Smith & Nephew SNATS were worth $375,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Smith & Nephew SNATS during the second quarter valued at approximately $13,812,000. Grandfield & Dodd LLC bought a new position in shares of Smith & Nephew SNATS in the second quarter valued at approximately $13,192,000. Public Employees Retirement System of Ohio bought a new position in shares of Smith & Nephew SNATS in the second quarter valued at approximately $2,170,000. Teachers Retirement System of The State of Kentucky lifted its stake in shares of Smith & Nephew SNATS by 51.0% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 905,100 shares of the medical equipment provider’s stock worth $28,764,000 after buying an additional 305,600 shares during the last quarter. Finally, BlackRock Inc. acquired a new stake in shares of Smith & Nephew SNATS in the second quarter worth $505,323,000. Institutional investors and hedge funds own 25.64% of the company’s stock.
Smith & Nephew SNATS Price Performance
SNN opened at $30.48 on Tuesday. Smith & Nephew SNATS, Inc. has a 1-year low of $26.12 and a 1-year high of $37.09. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. The business has a 50 day moving average of $28.26 and a 200-day moving average of $31.17.
Smith & Nephew SNATS Announces Dividend
The business also recently announced a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be given a dividend of $0.3120 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a yield of 236.0%.
Wall Street Analyst Weigh In
Several research firms recently issued reports on SNN. Weiss Ratings downgraded shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, September 24th. Bank of America downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a report on Tuesday, September 8th. Barclays lowered shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. BTIG Research started coverage on shares of Smith & Nephew SNATS in a research report on Monday, August 31st. They set a “neutral” rating for the company. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a report on Thursday, August 6th. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $31.91.
View Our Latest Stock Analysis on SNN
Smith & Nephew SNATS Company Profile
Smith & Nephew plc is a global medical technology company that develops and manufactures products used by healthcare professionals to treat injuries, manage wounds and restore patients’ mobility. Founded in 1856 by Thomas James Smith in Hull, England, the company has grown from a pharmacy business into an international healthcare manufacturer.
The company operates across three principal areas: orthopaedics, sports medicine and ear, nose and throat (ENT), and advanced wound management.
See Also
- Five stocks we like better than Smith & Nephew SNATS
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew SNATS, Inc. (NYSE:SNN – Free Report).
Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.
